Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of esketamine nasal spray in treatment-resistant major depressive disorder after TRD3013
2020-004291-18Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esketamine in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Primary endpoints: Intervention-emergent adverse events and Suicidal ideation and behavior. Started Feb 2021; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2020-004291-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004291-18.